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Previously, we reported that p90-RSK1 phosphorylates neuronal nitric oxide synthase (nNOS) at
Ser847 in cells treated with mitogens, leading to the inhibition of NOS activity. Here, we show
RSK1 Cys223 glutathionylation limits the activity of the enzyme following an oxidative stimulus
and attenuates the nNOS phosphorylation. Treatment of RSK1 with diamide/glutathione results in
inactivation of the enzyme in vitro. Mutagenesis studies conﬁrmed that S-glutathionylation of
Cys223 is both necessary and sufﬁcient for this inhibition of RSK1. In transfected cells expressing
RSK1 and nNOS, treatment with diamide caused a decrease in EGF-induced phosphorylation of nNOS
at Ser847. Cells expressing mutant RSK1 (C223S) proved resistant in this regard. Thus, RSK1 Cys223
glutathionylation may contribute to regulate the levels of NO in the brain.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The 90-kDa ribosomal S6 kinases (RSKs) are a family of serine/
threonine kinases that lie downstream of the Ras-mitogen-acti-
vated protein kinase (MAPK) cascade [1]. RSKs contain two func-
tional protein kinase domains, and in mammals four expressed
homologues (RSK1–4) have been identiﬁed. RSKs are activated by
extracellular-signal-regulated kinase 1/2 (ERK1/2) [2] and 3-phos-
phoinositide-dependent protein kinase 1 (PDK1) [3] by sequential
phosphorylations in the C-terminal kinase domain (CTKD) at
Thr573 and N-terminal kinase domain (NTKD) at Ser 221 [1],
respectively. When activated, RSK promotes the phosphorylation
of many cytosolic and nuclear targets that regulate diverse cellular
processes, including cell growth, proliferation, survival and motil-
ity [4].
Nitric oxide (NO) is a ubiquitous gaseous biologically active
messenger [5]. Physiological functions of NO in the central ner-
vous system include regulation of neurotransmission, neuropro-
tection and neurotoxicity [6]. NO is produced by neuronal NOsynthase (nNOS) in nervous tissue in both the central and
peripheral nervous system. It was shown that epidermal growth
factor (EGF) induces inactivation of nNOS through phosphoryla-
tion of Ser847 by RSK1, leading to the reduction of NO levels
[7]. In addition to NO, reactive oxygen species (ROS) are con-
stantly produced by a number of normal cellular events, with a
major source being aerobic respiration. Excessive ROS can induce
oxidative damage in cell constituents and promote a number of
degenerative diseases and aging [8]. Meanwhile, ROS are not only
injurious to cell survival but also essential to cell signaling and
regulation [9].
Studies have demonstrated that ROS can mediate the activa-
tion of the MAPK pathways [10]. A number of cellular stimuli
that induce ROS production can activate MAPK pathways in mul-
tiple cell types [10,11]. Moreover, direct exposure of cells to
exogenous hydrogen peroxide (H2O2) mimics oxidative stress
and leads to activation of MAPK pathways [12,13]. The mecha-
nism(s) by which ROS can regulate the MAPK pathways, how-
ever, is not well deﬁned. Because ROS can alter protein
structure and function by modifying critical amino acid residues
of proteins [9], the oxidative modiﬁcation of signaling proteins
by ROS may be one of the plausible mechanisms for the activa-
tion of MAPK pathways. However, the precise molecular target(s)
of ROS is unknown.
For the present paper, we investigated molecular mechanisms
of oxidant dependent regulation of RSK1 in cells and demonstrated
S-glutathionylation-mediated inactivation of the enzyme.
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2.1. Materials
RSK1 cDNA was cloned from a mouse brain cDNA library and
then cloned into pME18s-FLAG vector. The rabbit polyclonal anti-
body, NP847, recognizing phosphorylation at Ser847 on nNOS,
was prepared as described previously in [14]. Anti-nNOS poly-
clonal antibody was obtained from Santa Cruz Biotechnology (San-
ta Cruz, CA, USA). The rabbit anti-RSK1 antibody was obtained
from Sigma (St. Louis, MO, USA). Monoclonal antibody recognizing
glutathionylated proteins (anti-protein S-glutathionylation (anti-
PSSG) Ab) was obtained from Virogen (Watertown, MA, USA). Anti-
bodies against phosphor-ERK1/2 and ERK1/2 were odtained from
Cell Signaling Technology (Danvers, MA, USA). The human EGF
was from Roche. Diamide was purchased from Sigma. [c-32P] ATP
(6000 Ci/mmol) and ECL prime (enhanced chemiluminescence)
immunoblotting detection reagents were from Perkin–Elmer (Wal-
tham, MA, USA) and GE Healthcare (Piscataway, NJ, USA), respec-
tively. All other materials and reagents were of the highest
quality available from commercial suppliers.
2.2. Cell culture, transfection and stimulation
Human embryonic kidney (HEK293) cells were maintained in
Dulbecco’s modiﬁed Eagle medium containing 10% fetal calf serum
and sub-cultured for 24 h in 6-cm dishes. They were then transfec-
ted with the pME18s-FLAG-RSK1 construct (1 lg) using Lipofect-
amine LTX with Plus Reagent (Life Technologies, Inc.). After 24–
36 h incubation, the cells were serum starved for 18 h and stimu-
lated with buffer alone, 1 mM diamide for 15 min or 100 ng/ml
EGF for 10 min.
2.3. Preparation of lysates and immunoprecipitation
For preparation of lysates, cells were homogenized by sonica-
tion in TNE buffer (50 mM Tris–HCl, pH 7.5, 150 mM NaCl, 1 mM
PMSF, 10 lg/ml aprotinin, 1 mM sodium orthovanadate, 25 mM
sodium ﬂuoride, 10 mM sodium pyrophosphate, 0.1 mM EDTA,
0.1 mM EGTA, and 1% Nonidet P40). After centrifugation at
15000g for 15 min, the supernatant was added to 10 ll of anti-
FLAG M2-agarose afﬁnity gel (50% slurry) (Sigma), and the mixture
was incubated for 1 h at 4 C. After precipitation of the resin by
centrifugation and removal of the supernatant, resin was washed
twice with 500 ll of TNE buffer. RSK1 was eluted with 3 FLAG
Peptide (Sigma) from the beads. An aliquot of supernatant was also
applied for SDS–PAGE followed by Western blot analyses or for an
in vitro kinase assay. For the determination of glutathionylated
RSK1, all the procedures were performed without any reducing
reagents.
2.4. Inactivation of RSK1 by diamide and GSH
Puriﬁed RSK1 was incubated at 25 C for 10 min in 250 mM
HEPES (pH 7.5) and 0.5 mM EDTA with increasing amounts of dia-
mide (0–1 mM), in the presence of 100 lM glutathione (GSH). An
aliquot of reaction mixture was then removed and analyzed for
activity. Kinase activity was measured at 30 C for 10 min in
40 mM HEPES (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 10 lM [c-32P]
ATP, 50 lM S6 Kinase/Rsk Substrate Peptide 1 (Synthetic peptide
(RRRLSSLRA) corresponding to amino acids 231–239 of human
40S ribosomal protein S6) (Upstate), and RSK1 in a ﬁnal volume
of 25 ll. 32P incorporation was determined by spotting 20-ll ali-
quots onto Whatman P-81 phosphocellulose paper followed by
washing in 75 mM phosphoric acid [15]. For reversal with glutare-
doxin (AbFrontier, Seoul, Korea), following incubation with dia-mide and GSH, human recombinant glutaredoxin-1 (0.04 mg/ml)
and more GSH (500 lM) were added.
2.5. Construction of plasmids
The plasmids pME18s-nNOS was generated as described previ-
ously in [16]. The RSK1 mutants, C223S, (the mutant featuring
replacement of Cys223 with Ser) were generated with pME18s-
RSK1 plasmid DNA and a QuickChange II site-directed mutagenesis
kit (Stratagene, La Jolla, CA, USA). The nucleotide sequences of each
mutant were conﬁrmed.
2.6. Phosphorylation of recombinant nNOS in vitro
Recombinant rat nNOS was expressed in Escherichia coli and
puriﬁed using 20,50-ADP-agarose (Sigma), as described previously
in [17]. Puriﬁed nNOS (0.6 lg) was incubated with pretreated
RSK1 at 30 C for 10 min in a solution containing 40 mM HEPES
(pH 7.5), 10 mM MgCl2, 1 mM EGTA, 1 mM ATP for Western blot-
ting. The reaction was terminated by the addition of SDS sample
buffer. The samples were then subjected to SDS–PAGE followed
by Western blot analysis with the indicated antibody.
2.7. Statistical analysis
All results are represented as means ± S.E. of at least three
determinations. The statistical evaluation was performed using
one-way ANOVA test. We considered P < 0.05 to be statistical
signiﬁcant.
3. Results
3.1. RSK1 is inactivated by treatment with diamide and reduced GSH
In initial experiments we determined the effects of the thiol-
speciﬁc oxidant diamide with reduced GSH on RSK1 enzyme activ-
ity. For full activation, RSK1 requires phosphorylation of a crucial
activation loop Thr221 by PDK1 [3]. To obtain activated RSK1, we
expressed FLAG-RSK1 in HEK293 cells, treated with EGF (100 ng/
ml, 10 min) and puriﬁed with FLAG-agarose gel. Puriﬁed RSK1
was incubated with GSH (100 lM) and diamide (100 lM) for
10 min, and the activity of RSK1 was measured using a synthetic
peptide, S6 peptide, as a substrate. There was signiﬁcant loss in
the enzyme activity. Addition of dithiothreitol (DTT) (20 mM) al-
most completely reversed this inhibition (Fig. 1A). When puriﬁed
RSK1 was incubated with diamide (>100 lM) in the presence of
GSH (100 lM), there was a synergistic effect with rapid and near
complete inhibition occurring within 10 min (Fig. 1B).
3.2. RSK1 is modiﬁed by S-glutathionylation, resulting in enzyme
inhibition
To determine whether glutathionylated RSK1 could be gener-
ated by reaction of GSH with diamide, puriﬁed activated RSK1
was incubated either with or without GSH and diamide for
10 min, and then immunoblotted with a monoclonal antibody
against GSH protein adducts and anti-RSK1 antibody in the non-re-
duced condition. Note that the band at120 kDa of RSK1 was addi-
tionally observed by treatment with GSH and diamide besides
90 kDa of the enzyme (Fig. 2A). This treatment did induce RSK1
glutathionylation (Fig. 2A). Although S-glutathionylated RSK1
was evident in GSH/diamide-treated enzyme, we questioned
whether this modiﬁcation is sufﬁcient to signiﬁcantly dampen
RSK1 activity. The enzyme thioltransferase (also known as glutare-
doxin: Grx) selectively dethiolates S-glutathionylated protein by a
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Fig. 1. RSK1 is inactivated by diamide/GSH. (A) Puriﬁed RSK1 was incubated (10 min at 25 C) with 100 lM GSH and 100 lM diamide. Samples were then assayed for 10 min
using 50 lM S6 Kinase/Rsk Substrate Peptide 1 and 10 lM [c-32P] ATP. For the DTT sample, an additional incubation with 20 mM DTT (10 min at 25 C) was performed prior
to assaying. Values are means ± S.E. of three independent experiments are shown. (B) Puriﬁed RSK1 was incubated (10 min at 25 C) with the indicated amounts of diamide
(0.01–1 mM) in the presence of 100 lM GSH. The enzyme activity of RSK1 was measured as described in panel A. The means ± S.E. of three independent experiments are
shown.
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whether thioltransferase catalysis could reverse GSH/diamide-
potentiated RSK1 inactivation. When puriﬁed activated RSK1 was
incubated with GSH (100 lM) and diamide (100 lM) for 10 min,
its enzyme activity was inhibited. Treatment of Grx (3.3 lM) and
GSH (500 lM) with the glutathioylated RSK1 resulted in a substan-
tial reactivation of kinase activity (Fig. 2B). We next examined
whether Grx and GSH reverse kinase inhibition by removal of
GSH from RSK1. RSK1 was inactivated with GSH and diamide and
then was analyzed by immunoblotting with a monoclonal anti-
body against GSH protein adducts. The glutathioylated RSK1 with
the molecular weights of 90 and 120 kDa was decreased by
the treatment with Grx and GSH (Fig. 2B). On the other hand, the
total RSK1 at 120 kDa remained unchanged by the treatment
with Grx and GSH.3.3. Cys223 is an essential site for inactivation of RSK1
We previously showed that Ca2+/CaM-dependent protein kinase
I is fully and reversibly inactivated by oxidative S-glutathionylation
at Cys179 [19]. This Cys179 in the subdomain VIII, often mentioned
as a key protein kinase catalytic domain indicator [20], is highly
conserved among a number of kinases including RSK1 (Cys223:
based on the mouse RSK1 sequence). We generated a mutant
FLAG-RSK1 in which Ser was substituted for Cys223 (C223S) and
characterized both activity and sensitivity to inhibition by GSH
and diamide. FLAG-RSK1 wild-type (WT) or C223S mutant was
overexpressed in cells and puriﬁed by FLAG–agarose gel from cell
lysates, and gave a major band at 90 kDa on Western blot with
anti-RSK1 antibody (Fig. 3A). The enzyme activities of WT and
C223S mutants were similar in an in vitro assay. With increasing
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Table 1
Kinetic properties of diamide/GSH-untreated (control activity) and -treated RSK1
phosphorylation reaction was carried out at 30 C for 10 min in a solution containing
50 lM S6 peptide, and 10 lM [c-32P] ATP, as standard condition (standard). The
values represent the means ± S.E. of three experiments.
Control activity (fmol/min) Diamide/GSH
Standard 27.21 ± 1.93 11.19 ± 0.15
Excess S6 peptide (500 lM) 52.71 ± 2.78 22.15 ± 0.84
Excess ATP (100 lM) 217.02 ± 3.23 75.70 ± 4.35
1684 T. Takata et al. / FEBS Letters 587 (2013) 1681–1686amounts of diamide (0.01–1 mM) in the presence of GSH (100 lM)
no remarkable decrease in activity was noted with the C223S mu-
tant, while the WT was signiﬁcantly inactivated (Fig. 3B).
Our previous data showed that RSK1 inhibits neuronal NO syn-
thase (nNOS) enzyme activity by adding phosphate groups to
Ser847 on nNOS [7]. We further examined the effect of RSK1 inac-
tivation by diamide and GSH on nNOS phosphorylation. Puriﬁed
activated RSK1 was incubated with GSH (100 lM) and diamide
(0.01–1 mM) for 10 min, and the phosphorylation of nNOS at
Ser847 by the glutathionylated RSK1 was monitored using phos-
pho-Ser847 nNOS antibody. In the absence of treatment, the nNOS
phosphorylation at Ser847 was evident in both RSK1 WT and
C223S mutant. Treatment of RSK1 WT with diamide (>100 lM)/
GSH (100 lM) led to decrease in the nNOS phosphorylation
(Fig. 3C). In contrast, C223S mutant proved resistant to diamide/
GSH treatment. The treatment of diamide and GSH led to increase
in S-glutathionylation of RSK1. Amount of S-glutathionylation of
RSK1 WT was more than that of C223S mutant. The upper band
at 120 kDa of RSK1 was observed by the treatment of diamide/
GSH in RSK1 WT but not in C223S mutant.
3.4. Cys223 is the site of S-glutathionylation on RSK1 in cells
Having discerned that S-glutathionylation of Cys223 inactivates
RSK1, we tested whether RSK1 substrates (ATP, S6 peptide) can
protect against inactivation. The inhibition of RSK1 by diamide
and GSH was competitive with neither ATP nor S6 peptide. Table 1summarized the properties of the RSK1 WT treated either with or
without GSH and diamide.
We further examined the working of this Cys223-sensitive re-
dox signaling in situ. HEK293 cells were transfected with nNOS
alone or with RSK1 WT or RSK1 C223S, and treated with combina-
tion of EGF and diamide. Then, cell lysates were immunoblotted
with phospho-Ser847 nNOS antibody. When nNOS-expressing
cells were treated with EGF, phosphorylation of Ser847 was ob-
served as described previously (Fig. 4) [7]. Treatment of the cells
with diamide almost completely blocked EGF-induced phosphory-
lation of Ser847. When nNOS/RSK1 WT or nNOS/RSK1 C223S
-expressing cells were treated with EGF, phosphorylation of
Ser847 was observed in both cells. Treatment of the cells express-
ing nNOS/RSK1 WT with diamide led to decrease in the EGF-in-
duced nNOS phosphorylation (Fig. 4). In contrast, cells expressing
nNOS/RSK1 C223S proved resistant to diamide. Note that EGF-, dia-
mide-, and EGF/diamide-induced phosphorylation of ERK1/2, the
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induced S-glutathionylation of WT was more evident than C223S
mutant.
4. Discussion
We showed here at the ﬁrst time that RSK1 is sensitive to inhi-
bition by direct S-glutathionylation of its Cys223 residue during
oxidative stress. Activation of RSK1 is regulated by its upstream ki-
nases, ERK1/2 and PDK1, by sequential phosphorylations. These
sequential phosphorylations of the enzyme are initiated by ERK1/
2 at Thr573 of CTKD leading to the autophosphorylation of RSK1
at Ser380. This phosphorylation allows the dockage of PDK1 and
enables PDK1-dependent phosphorylation in the NTKD of RSK1
at Ser221, resulting in its maximal activation [1,2]. Since Cys575
in the CTKD of RSK1 is highly conserved among a number of ki-
nases, we also generated mutant of RSK1 (C575S), in which
Cys575 residue of CTKD was replaced by Ser and determined both
activity and sensitivity to inhibition by GSH and diamide. The en-
zyme activities of WT and C575S mutant were similar in an
in vitro assay. Treatment of the WT and C575S mutant with GSH
(100 lM) and diamide (100 lM) for 10 min resulted in a nearly
complete inhibition of enzyme activity using nNOS as a substrate
(data not shown). The oxidative stress prior to EGF stimulation re-
sults in inhibition of the RSK1 activation in cells (Fig. 4), and the
EGF-induced activation of RSK1 activity was also inhibited by
oxidative stress in vitro (Figs. 1–3). Thus, inhibition of RSK1 by
its S-glutathionylation at Cys223 appears to be dominant over acti-
vation of the kinase by its phosphorylation at Ser221. An additional
120 kDa band of RSK1WTwas observed by the treatment of GSH/
diamide but not in the case of C223S mutant, determined with
non-reducing SDS–PAGE (Figs. 2–4). In addition, this 120 kDa
band of RSK1 was detected when glutathioylated RSK1 WT was
treated with Grx and GSH (Fig. 2), indicating that Cys223 also con-
tributes to another oxidative modiﬁcation of the enzyme besides
its S-glutathionylation. However, our data clearly indicate that
the oxidative stress-induced inactivation of RSK1 is occurred via
its S-glutathionylation at Cys223 in cells. Because diamide has
many potential actions that could function to inﬂuence the ERK
pathway, including inhibiting thiol containing protein phosphatases[21], additional studies are needed to elucidate how diamide is
activating ERK. We also examined the working of this Cys223-sen-
sitive redox signaling using H2O2 or NO as an oxidative stress.
Although the sensitivity of RSK1 to regulation by NO was not ob-
served, H2O2 treatment led to a decrease in the enzyme activity
of RSK1 WT but not of the C223S mutant (data not shown). Thus,
it remains to be determined whether other oxidative modiﬁcations
of RSK1 at Cys223 were involved in an oxidative-induced inactiva-
tion of the enzyme besides its S-glutathionylation. Active ERK1/2
has many intracellular targets located in nucleus, cytoplasm and
cell surface. All of these ERK substrates seem to play an important
role in controlling cellular processes that occur on mitogenic stim-
ulation. One of the ERK1/2 substrates, RSK1 is a central mediator of
ERK1/2 during cell survival [22]. The phosphorylation of ERK1/2
was increased following treatment with either EGF or diamide in
cells (Fig. 4). Treatment of the cells expressing nNOS with EGF re-
sulted in an increase in the phosphorylation of nNOS at Ser847, but
diamide had no effect on the nNOS phosphorylation. Thus, diamide
is through to inhibit RSK1 activity via its S-glutathionylation at
Cys223 in cells. Indeed, treatment of the cells expressing nNOS/
RSK1 C223S with diamide resulted in a similar increase in the
phosphorylation of nNOS at Ser847 as with EGF (Fig. 4).
Under what cellular conditions may RSK1 be glutathionylated
and inactivated? RSKs are broadly expressed in the brain that reg-
ulate important cellular functions, including cell survival [23].
Inhibition of NOS has been shown to be neuroprotective, implicat-
ing NOS in the production of radicals which can produce peroxyni-
trite and H2O2 [24]. Following EGF treatment, nNOS was
phosphorylated by RSK1 in rat hippocampal neurons and cerebel-
lar granule cells, which suggests a novel role for RSK1 in the regu-
lation of NO function in the brain [7]. We began to investigate
whether diamide treatment is regulating NO production in WT
and in mutant RSK1 expressing cells. The brain is highly suscepti-
ble to oxidative stress due to its requirement for excessive use of
glucose for energy, as well as its inability to undergo cellular regen-
eration. Indeed, various indices of ROS damage have been reported
within the speciﬁc brain region that undergoes selective neurode-
generation [25]. Huntington’s disease is an autosomal dominant
disease that causes degeneration of medium spiny GABAergic neu-
rons, expressing nNOS in the striatum. The expression levels of and
1686 T. Takata et al. / FEBS Letters 587 (2013) 1681–1686the activities of RSK1/RSK2 are increased in the striatum of Hun-
tington’s disease animal models [26]. We showed here that EGF-in-
duced nNOS phosphorylation at Ser847 was inhibited during
oxidative stress through the glutathionylation of RSK1 at Cys223
in cells (Fig. 4). We speculate that the RSK1 Cys223 glutathionyla-
tion enhances the accumulation of toxic levels of NO in the brain. It
needs to be determined in future study whether oxidative stress
regulates NO production via RSK1 inactivation.Acknowledgments
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